Polymorphic transporters and platinum pharmacodynamics

Drug Metabolism and Pharmacokinetics

Volumn 28, Issue 1, 2013, Pages 19-27

  Sprowl, Jason A ^a   Ness, Rachel A ^a   Sparreboom, Alex ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Carboplatin; Cisplatin; Drug disposition; Oxaliplatin; Pharmacodynamics; SNPs; Solute carriers

Indexed keywords

ABC TRANSPORTER; ATP BINDING CASSETTE PROTEIN FAMILY C2; ATP BINDING CASSETTE PROTEIN FAMILY C4; ATP BINDING CASSETTE PROTEIN FAMILY C5; CARBOPLATIN; CELECOXIB; CIMETIDINE; CISPLATIN; COPPER TRANSPORTER 1; CYSTATIN C; MENKES PROTEIN; METFORMIN; MULTIDRUG AND TOXIN EXTRUSION 1 TRANSPORTER; MULTIDRUG AND TOXIN EXTRUSION 2 TRANSPORTER; MULTIDRUG RESISTANCE PROTEIN; NEDAPLATIN; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; ORGANIC CATION TRANSPORTER 3; OXALIPLATIN; PICOPLATIN; PLATINUM COMPLEX; SMALL INTERFERING RNA; THYMOQUINONE; UNCLASSIFIED DRUG; WILSON DISEASE PROTEIN;

ABCC4 GENE; ABCC5 GENE; ANTINEOPLASTIC ACTIVITY; ATP7B GENE; BONE MARROW SUPPRESSION; CANCER SURVIVAL; CELL MEMBRANE; COLORECTAL CANCER; CREATININE BLOOD LEVEL; DRUG APPROVAL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG STRUCTURE; GENE EXPRESSION; GENETIC POLYMORPHISM; GLOMERULUS FILTRATION RATE; HEAD AND NECK CANCER; HEARING IMPAIRMENT; HUMAN; IC 50; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CLEARANCE; LIPID BILAYER; LOSS OF FUNCTION MUTATION; LUNG NON SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; METASTASIS POTENTIAL; MOTOR NEUROPATHY; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NONHUMAN; OCT1 GENE; OTOTOXICITY; OVERALL SURVIVAL; PHARMACODYNAMICS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; REVIEW; SENSORY NEUROPATHY; SIDE EFFECT; SLC22A1 GENE; SLC22A2 GENE; SLC22A3 GENE; SLC22A5 GENE; SLC22A6 GENE; SLC31A1 GENE; SLC47A1 GENE; SLC47A2 GENE; TESTIS CANCER; TREATMENT OUTCOME;

EID: 84874625728     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-12-RV-073     Document Type: Review

References (123)

1. Horn, L., Castellanos, E. L. and Johnson, D. H.: Update on new drugs in small cell lung cancer. Expert Opin. Investig. Drugs, 20: 441-455 (2011).
2. Shelley, M. D., Cleves, A., Wilt, T. J. and Mason, M. D.: Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma. BJU Int., 108: 168-179 (2011).
3. Collins, I. M., Roberts-Thomson, R., Faulkner, D., Rischin, D., Friedlander, M. and Mileshkin, L.: Carboplatin Dosing in Ovarian Cancer: Problems and Pitfalls. Int. J. Gynecol. Cancer, 7: 1213-1218 (2011).
4. Nichols, C. and Kollmannsberger, C.: First-line chemotherapy of disseminated germ cell tumors. Hematol. Oncol. Clin. North Am., 25: 543-556, viii (2011).
5. Chitapanarux, I., Tharavichitkul, E., Lorvidhaya, V., Sittitrai, P. and Pattarasakulchai, T.: Induction chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer. Biomed. Imaging Interv. J., 6: e23 (2010).
6. Goldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C. and Alberts, S. R.: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol., 22: 23-30 (2004).
7. Zwelling, L. A. and Kohn, K. W.: Mechanism of action of cisdichlorodiammineplatinum(II). Cancer Treat. Rep., 63: 1439-1444 (1979).
8. Siddik, Z. H.: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene, 22: 7265-7279 (2003).
9. Higby, D. J., Wallace, H. J., Jr., Albert, D. J. and Holland, J. F.: Diaminodichloroplatinum: a phase I study showing responses in testicular and other tumors. Cancer, 33: 1219-1225 (1974).
10. McWhinney, S. R., Goldberg, R. M. and McLeod, H. L.: Platinum neurotoxicity pharmacogenetics. Mol. Cancer Ther., 8: 10-16 (2009).
11. Raghavan, D.: Testicular cancer: maintaining the high cure rate. Oncology (Williston Park), 17: 218-228; discussion 228-219, 234-215, passim (2003).
12. Ardizzoni, A., Boni, L., Tiseo, M., Fossella, F. V., Schiller, J. H., Paesmans, M., Radosavljevic, D., Paccagnella, A., Zatloukal, P., Mazzanti, P., Bisset, D. and Rosell, R.: Cisplatin versus carboplatinbased chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J. Natl. Cancer Inst., 99: 847-857 (2007).
13. Rajeswaran, A., Trojan, A., Burnand, B. and Giannelli, M.: Efficacy and side effects of cisplatin and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer, 59: 1-11 (2008).
14. Schuler, P. J., Trellakis, S., Greve, J., Bas, M., Bergmann, C., Bolke, E., Lehnerdt, G., Mattheis, S., Albers, A. E., Brandau, S., Lang, S., Whiteside, T. L., Bier, H. and Hoffmann, T. K.: In vitro chemosensitivity of head and neck cancer cell lines. Eur. J. Med. Res., 15: 337-344 (2010).
15. Ibrahim, A., Hirschfeld, S., Cohen, M. H., Griebel, D. J., Williams, G. A. and Pazdur, R.: FDA drug approval summaries: oxaliplatin. Oncologist, 9: 8-12 (2004).
16. Rixe, O., Ortuzar, W., Alvarez, M., Parker, R., Reed, E., Paull, K. and Fojo, T.: Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem. Pharmacol., 52: 1855-1865 (1996).
17. Raymond, E., Faivre, S., Chaney, S., Woynarowski, J. and Cvitkovic, E.: Cellular and molecular pharmacology of oxaliplatin. Mol. Cancer Ther., 1: 227-235 (2002).
18. Mishima, M., Samimi, G., Kondo, A., Lin, X. and Howell, S. B.: The cellular pharmacology of oxaliplatin resistance. Eur. J. Cancer, 38: 1405-1412 (2002).
19. Gale, G. R., Morris, C. R., Atkins, L. M. and Smith, A. B.: Binding of an antitumor platinum compound to cells as influenced by physical factors and pharmacologically active agents. Cancer Res., 33: 813-818 (1973).
20. Binks, S. P. and Dobrota, M.: Kinetics and mechanism of uptake of platinum-based pharmaceuticals by the rat small intestine. Biochem. Pharmacol., 40: 1329-1336 (1990).
21. Dobson, P. D., Lanthaler, K., Oliver, S. G. and Kell, D. B.: Implications of the dominant role of transporters in drug uptake by cells. Curr. Top. Med. Chem., 9: 163-181 (2009).
22. Nelson, J. A., Santos, G. and Herbert, B. H.: Mechanisms for the renal secretion of cisplatin. Cancer Treat. Rep., 68: 849-853 (1984).
23. Gründemann, D., Gorboulev, V., Gambaryan, S., Veyhl, M. and Koepsell, H.: Drug excretion mediated by a new prototype of polyspecific transporter. Nature, 372: 549-552 (1994).
24. Gorboulev, V., Ulzheimer, J. C., Akhoundova, A., Ulzheimer-Teuber, I., Karbach, U., Quester, S., Baumann, C., Lang, F., Busch, A. E. and Koepsell, H.: Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol., 16: 871-881 (1997).
25. Tzvetkov, M. V., Vormfelde, S. V., Balen, D., Meineke, I., Schmidt, T., Sehrt, D., Sabolic, I., Koepsell, H. and Brockmoller, J.: The effects ofgenetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin. Pharmacol. Ther., 86: 299-306 (2009).
26. Yonezawa, A., Masuda, S., Nishihara, K., Yano, I., Katsura, T. and Inui, K.: Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem. Pharmacol., 70: 1823-1831 (2005).
27. Yonezawa, A., Masuda, S., Yokoo, S., Katsura, T. and Inui, K.: Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J. Pharmacol. Exp. Ther., 319: 879-886 (2006).
28. Tzvetkov, M. V., Behrens, G., O'Brien, V. P., Hohloch, K., Brockmoller, J. and Benohr, P.: Pharmacogenetic analyses of cisplatin-induced nephrotoxicity indicate a renoprotective effect of ERCC1 polymorphisms. Pharmacogenomics, 12: 1417-1427 (2011).
29. Yokoo, S., Yonezawa, A., Masuda, S., Fukatsu, A., Katsura, T. and Inui, K.: Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem. Pharmacol., 74: 477-487 (2007).
30. Zhang, S., Lovejoy, K. S., Shima, J. E., Lagpacan, L. L., Shu, Y., Lapuk, A., Chen, Y., Komori, T., Gray, J. W., Chen, X., Lippard, S. J. and Giacomini, K. M.: Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res., 66: 8847-8857 (2006).
31. More, S. S., Li, S., Yee, S. W., Chen, L., Xu, Z., Jablons, D. M. and Giacomini, K. M.: Organic cation transporters modulate the uptake and cytotoxicity of picoplatin, a third-generation platinum analogue. Mol. Cancer Ther., 9: 1058-1069 (2010).
32. Li, S., Chen, Y., Zhang, S., More, S. S., Huang, X. and Giacomini, K. M.: Role of organic cation transporter 1, OCT1 in the pharmacokinetics and toxicity of cis-diammine(pyridine)chloroplatinum(II) and oxaliplatin in mice. Pharm. Res., 28: 610-625 (2011).
33. Motohashi, H., Sakurai, Y., Saito, H., Masuda, S., Urakami, Y., Goto, M., Fukatsu, A., Ogawa, O. and Inui, K.: Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol., 13: 866-874 (2002).
34. Nies, A. T., Herrmann, E., Brom, M. and Keppler, D.: Vectorial transport of the plant alkaloid berberine by double-transfected cells expressing the human organic cation transporter 1 (OCT1, SLC22A1) and the efflux pump MDR1 P-glycoprotein (ABCB1.) Naunyn Schmiedebergs Arch. Pharmacol., 376: 449-461 (2008).
35. Ciarimboli, G., Deuster, D., Knief, A., Sperling, M., Holtkamp, M., Edemir, B., Pavenstadt, H., Lanvers-Kaminsky, C., am Zehnhoff-Dinnesen, A., Schinkel, A. H., Koepsell, H., Jurgens, H. and Schlatter, E.: Organic cation transporter 2 mediates cisplatin-induced oto and nephrotoxicity and is a target for protective interventions. Am. J. Pathol., 176: 1169-1180 (2010).
36. Filipski, K. K., Loos, W. J., Verweij, J. and Sparreboom, A.: Interaction of Cisplatin with the human organic cation transporter 2. Clin. Cancer Res., 14: 3875-3880 (2008).
37. Burger, H., Zoumaro-Djayoon, A., Boersma, A. W., Helleman, J., Berns, E. M., Mathijssen, R. H., Loos, W. J. and Wiemer, E. A.: Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br. J. Pharmacol., 159: 898-908 (2010).
38. Filipski, K. K., Mathijssen, R. H., Mikkelsen, T. S., Schinkel, A. H. and Sparreboom, A.: Contribution of organic cation transporter 2 (OCT2) to cisplatin-induced nephrotoxicity. Clin. Pharmacol. Ther., 86: 396-402 (2009).
39. Franke, R. M., Kosloske, A. M., Lancaster, C. S., Filipski, K. K., Hu, C., Zolk, O., Mathijssen, R. H. and Sparreboom, A.: Influence of Oct1/ Oct2-deficiency on cisplatin-induced changes in urinary N-acetyl-beta-D-glucosaminidase. Clin. Cancer Res., 16: 4198-4206 (2010).
40. Katsuda, H., Yamashita, M., Katsura, H., Yu, J., Waki, Y., Nagata, N., Sai, Y. and Miyamoto, K.: Protecting cisplatin-induced nephrotoxicity with cimetidine does not affect antitumor activity. Biol. Pharm. Bull.,33: 1867-1871 (2010).
41. Huang, Q., Dunn, R. T., 2nd, Jayadev, S., DiSorbo, O., Pack, F. D., Farr, S. B., Stoll, R. E. and Blanchard, K. T.: Assessment of cisplatin-induced nephrotoxicity by microarray technology. Toxicol. Sci., 63: 196-207 (2001).
42. Slitt, A. L., Cherrington, N. J., Hartley, D. P., Leazer, T. M. and Klaassen, C. D.: Tissue distribution and renal developmental changes in rat organic cation transporter mRNA levels. Drug Metab. Dispos., 30: 212-219 (2002).
43. Alnouti, Y., Petrick, J. S. and Klaassen, C. D.: Tissue distribution and ontogeny of organic cation transporters in mice. Drug Metab. Dispos., 34: 477-482 (2006).
44. Song, I. S., Shin, H. J., Shim, E. J., Jung, I. S., Kim, W. Y., Shon, J. H. and Shin, J. G.: Genetic variants of the organic cation transporter 2 influence the disposition of metformin. Clin. Pharmacol. Ther., 84: 559-562 (2008).
45. Iwata, K., Aizawa, K., Kamitsu, S., Jingami, S., Fukunaga, E., Yoshida, M., Yoshimura, M., Hamada, A. and Saito, H.: Effects of genetic variants in SLC22A2 organic cation transporter 2 and SLC47A1 multidrug and toxin extrusion 1 transporter on cisplatin-induced adverse events. Clin. Exp. Nephrol., 16: 843-851 (2012).
46. Zhang, J. and Zhou, W.: Ameliorative effects of SLC22A2 gene polymorphism 808 G/T and cimetidine on cisplatin-induced nephrotoxicity in Chinese cancer patients. Food Chem. Toxicol., 50: 2289-2293 (2012).
47. Koepsell, H., Lips, K. and Volk, C.: Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res., 24: 1227-1251 (2007).
48. Tamai, I., Ohashi, R., Nezu, J., Yabuuchi, H., Oku, A., Shimane, M., Sai, Y. and Tsuji, A.: Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J. Biol. Chem., 273: 20378-20382 (1998).
49. Lancaster, C. S., Hu, C., Franke, R. M., Filipski, K. K., Orwick, S. J., Chen, Z., Zuo, Z., Loos, W. J. and Sparreboom, A.: Cisplatin-induced downregulation of OCTN2 affects carnitine wasting. Clin. Cancer Res., 16: 4789-4799 (2010).
50. Jong, N. N., Nakanishi, T., Liu, J. J., Tamai, I. and McKeage, M. J.: Oxaliplatin Transport Mediated by Organic Cation/Carnitine Transporters OCTN1 and OCTN2 in Overexpressing Human Embryonic Kidney 293 Cells and Rat Dorsal Root Ganglion Neurons. J. Pharmacol. Exp. Ther., 338: 537-547 (2011).
51. Otsuka, M., Matsumoto, T., Morimoto, R., Arioka, S., Omote, H. and Moriyama, Y.: A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl. Acad. Sci. USA, 102: 17923-17928 (2005).
52. Tsuda, M., Terada, T., Asaka, J., Ueba, M., Katsura, T. and Inui, K.: Oppositely directed H+ gradient functions as a driving force of rat H+/ organic cation antiporter MATE1. Am. J. Physiol. Renal Physiol., 292: F593-F598 (2007).
53. Nakamura, T., Yonezawa, A., Hashimoto, S., Katsura, T. and Inui, K.: Disruption of multidrug and toxin extrusion MATE1 potentiates cisplatin-induced nephrotoxicity. Biochem. Pharmacol., 80: 1762-1767 (2010).
54. Masuda, S., Terada, T., Yonezawa, A., Tanihara, Y., Kishimoto, K., Katsura, T., Ogawa, O. and Inui, K.: Identification and functional characterization of a new human kidney-specific H+/organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol., 17: 2127-2135 (2006).
55. Matsushima, S., Maeda, K., Inoue, K., Ohta, K. Y., Yuasa, H., Kondo, T., Nakayama, H., Horita, S., Kusuhara, H. and Sugiyama, Y.: The nhibition of human multidrug and toxin extrusion 1 is involved in the drug-drug interaction caused by cimetidine. Drug Metab. Dispos., 37: 555-559 (2009).
56. Ohta, K. Y., Inoue, K., Yasujima, T., Ishimaru, M. and Yuasa, H.: Functional characteristics of two human MATE transporters: kinetics of cimetidine transport and profiles of inhibition by various compounds. J. Pharm. Pharm. Sci., 12: 388-396 (2009).
57. Tsuda, M., Terada, T., Ueba, M., Sato, T., Masuda, S., Katsura, T. and Inui, K.: Involvement of human multidrug and toxin extrusion 1 in the drug interaction between cimetidine and metformin in renal epithelial cells. J. Pharmacol. Exp. Ther., 329: 185-191 (2009).
58. Kajiwara, M., Terada, T., Ogasawara, K., Iwano, J., Katsura, T., Fukatsu, A., Doi, T. and Inui, K.: Identification of multidrug and toxin extrusion (MATE1 and MATE2-K) variants with complete loss of transport activity. J. Hum. Genet., 54: 40-46 (2009).
59. Toyama, K., Yonezawa, A., Tsuda, M., Masuda, S., Yano, I., Terada, T., Osawa, R., Katsura, T., Hosokawa, M., Fujimoto, S., Inagaki, N. and Inui, K.: Heterozygous variants of multidrug and toxin extrusions (MATE1 and MATE2-K) have little influence on the disposition of metformin in diabetic patients. Pharmacogenet. Genomics, 20: 135-138 (2010).
60. Nose, Y., Rees, E. M. and Thiele, D. J.: Structure of the Ctr1 copper trans'PORE'ter reveals novel architecture. Trends Biochem. Sci., 31: 604-607 (2006).
61. Lee, J., Pena, M. M., Nose, Y. and Thiele, D. J.: Biochemical characterization of the human copper transporter Ctr1. J. Biol. Chem., 277: 4380-4387 (2002).
62. Lee, J., Prohaska, J. R. and Thiele, D. J.: Essential role for mammaliancopper transporter Ctr1 in copper homeostasis and embryonic development. Proc. Natl. Acad. Sci. USA, 98: 6842-6847 (2001).
63. Zhou, B. and Gitschier, J.: hCTR1: a human gene for copper uptake identified by complementation in yeast. Proc. Natl. Acad. Sci. USA, 94: 7481-7486 (1997).
64. Ishida, S., Lee, J., Thiele, D. J. and Herskowitz, I.: Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc. Natl. Acad. Sci. USA, 99: 14298-14302 (2002).
65. Larson, C. A., Blair, B. G., Safaei, R. and Howell, S. B.: The role of the mammalian copper transporter 1 in the cellular accumulation of platinum-based drugs. Mol. Pharmacol., 75: 324-330 (2009).
66. Lin, X., Okuda, T., Holzer, A. and Howell, S. B.: The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol. Pharmacol., 62: 1154-1159 (2002).
67. Holzer, A. K., Manorek, G. H. and Howell, S. B.: Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol. Pharmacol., 70: 1390-1394 (2006).
68. Pabla, N., Murphy, R. F., Liu, K. and Dong, Z.: The copper transporter Ctr1 contributes to cisplatin uptake by renal tubular cells during cisplatin nephrotoxicity. Am. J. Physiol. Renal Physiol., 296: F505-F511 (2009).
69. Liu, J. J., Jamieson, S. M., Subramaniam, J., Ip, V., Jong, N. N., Mercer, J. F. and McKeage, M. J.: Neuronal expression of copper transporter 1 in rat dorsal root ganglia: association with platinum neurotoxicity. Cancer Chemother. Pharmacol., 64: 847-856 (2009).
70. More, S. S., Akil, O., Ianculescu, A. G., Geier, E. G., Lustig, L. R. and Giacomini, K. M.: Role of the copper transporter, CTR1, in platinuminduced ototoxicity. J. Neurosci., 30: 9500-9509 (2010).
71. Matsumoto, S., Tanaka, T., Kurokawa, H., Matsuno, K., Hayashida, Y. and Takahashi, T.: Effect of copper and role of the copper transporters ATP7A and CTR1 in intracellular accumulation of cisplatin. Anticancer Res., 27: 2209-2216 (2007).
72. Zisowsky, J., Koegel, S., Leyers, S., Devarakonda, K., Kassack, M. U., Osmak, M. and Jaehde, U.: Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem. Pharmacol., 73: 298-307 (2007).
73. Maryon, E. B., Zhang, J., Jellison, J. W. and Kaplan, J. H.: Human copper transporter 1 lacking O-linked glycosylation is proteolytically cleaved in a Rab9-positive endosomal compartment. J. Biol. Chem., 284: 28104-28114 (2009).
74. Xu, X., Ren, H., Zhou, B., Zhao, Y., Yuan, R., Ma, R., Zhou, H. and Liu, Z.: Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients. Lung Cancer, 77: 438-442 (2012).
75. Blair, B. G., Larson, C. A., Safaei, R. and Howell, S. B.: Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin. Cancer Res., 15: 4312-4321 (2009).
76. Murata, Y., Kodama, H., Abe, T., Ishida, N., Nishimura, M., Levinson, B., Gitschier, J. and Packman, S.: Mutation analysis and expression of the mottled gene in the macular mouse model of Menkes disease. Pediatr. Res., 42: 436-442 (1997).
77. Tanzi, R. E., Petrukhin, K., Chernov, I., Pellequer, J. L., Wasco, W., Ross, B., Romano, D. M., Parano, E., Pavone, L., Brzustowicz, L. M. et al.: The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat. Genet., 5: 344-350 (1993).
78. Suzuki, M. and Gitlin, J. D.: Intracellular localization of the Menkes and Wilson's disease proteins and their role in intracellular copper transport. Pediatr. Int., 41: 436-442 (1999).
79. Komatsu, M., Sumizawa, T., Mutoh, M., Chen, Z. S., Terada, K., Furukawa, T., Yang, X. L., Gao, H., Miura, N., Sugiyama, T. and Akiyama, S.: Copper-transporting P-type adenosine triphosphatase (ATP7B) is associated with cisplatin resistance. Cancer Res., 60: 1312-1316 (2000).
80. Samimi, G., Katano, K., Holzer, A. K., Safaei, R. and Howell, S. B.: Modulation of the cellular pharmacology of cisplatin and its analogs by the copper exporters ATP7A and ATP7B. Mol. Pharmacol., 66: 25-32 (2004).
81. Kanzaki, A., Toi, M., Neamati, N., Miyashita, H., Oubu, M., Nakayama, K., Bando, H., Ogawa, K., Mutoh, M., Mori, S., Terada, K., Sugiyama, T., Fukumoto, M. and Takebayashi, Y.: Copper-transporting P-type adenosine triphosphatase (ATP7B) is expressed in human breast carcinoma. Jpn. J. Cancer Res., 93: 70-77 (2002).
82. Nakayama, K., Kanzaki, A., Ogawa, K., Miyazaki, K., Neamati, N. and Takebayashi, Y.: Copper-transporting P-type adenosine triphosphatase (ATP7B) as a cisplatin based chemoresistance marker in ovarian carcinoma: comparative analysis with expression of MDR1, MRP1, MRP2, LRP and BCRP. Int. J. Cancer, 101: 488-495 (2002).
83. Nakagawa, T., Inoue, Y., Kodama, H., Yamazaki, H., Kawai, K., Suemizu, H., Masuda, R., Iwazaki, M., Yamada, S., Ueyama, Y., Inoue, H. and Nakamura, M.: Expression of copper-transporting P-type adenosine triphosphatase (ATP7B) correlates with cisplatin resistance in human non-small cell lung cancer xenografts. Oncol. Rep., 20: 265-270 (2008).
84. Martinez-Balibrea, E., Martinez-Cardus, A., Musulen, E., Gines, A., Manzano, J. L., Aranda, E., Plasencia, C., Neamati, N. and Abad, A.: Increased levels of copper efflux transporter ATP7B are associated with poor outcome in colorectal cancer patients receiving oxaliplatin-based chemotherapy. Int. J. Cancer, 124: 2905-2910 (2009).
85. Samimi, G., Varki, N. M., Wilczynski, S., Safaei, R., Alberts, D. S. and Howell, S. B.: Increase in expression of the copper transporter ATP7A during platinum drug-based treatment is associated with poor survival in ovarian cancer patients. Clin. Cancer Res., 9: 5853-5859 (2003).
86. Li, Z. H., Qiu, M. Z., Zeng, Z. L., Luo, H. Y., Wu, W. J., Wang, F., Wang, Z. Q., Zhang, D. S., Li, Y. H. and Xu, R. H.: Copper-transporting P-type adenosine triphosphatase (ATP7A) is associated with platinumresistance in non-small cell lung cancer (NSCLC). J. Transl. Med., 10: 21 (2012).
87. Ip, V., Liu, J. J., Mercer, J. F. and McKeage, M. J.: Differential expression of ATP7A, ATP7B and CTR1 in adult rat dorsal root ganglion tissue. Mol. Pain, 6: 53 (2010).
88. Fukushima-Uesaka, H., Saito, Y., Maekawa, K., Kurose, K., Sugiyama, E., Katori, N., Kaniwa, N., Hasegawa, R., Hamaguchi, T., Eguchi-Nakajima, T., Kato, K., Yamada, Y., Shimada, Y., Yoshida, T., Yamamoto, N., Nokihara, H., Kunitoh, H., Ohe, Y., Tamura, T., Ura, T., Saito, M., Muro, K., Doi, T., Fuse, N., Yoshino, T., Ohtsu, A., Saijo, N., Matsumura, Y., Okuda, H. and Sawada, J.: Genetic polymorphisms of copper and platinum drug-efflux transporters ATP7A and ATP7B in Japanese cancer patients. Drug Metab. Pharmacokinet., 24: 565-574 (2009).
89. van Aubel, R. A., Smeets, P. H., Peters, J. G., Bindels, R. J. and Russel, F. G.: The MRP4/ABCC4 gene encodes a novel apical organic anion transporter in human kidney proximal tubules: putative efflux pump for urinary cAMP and cGMP. J. Am. Soc. Nephrol., 13: 595-603 (2002).
90. König, J., Nies, A. T., Cui, Y., Leier, I. and Keppler, D.: Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance. Biochim. Biophys. Acta, 1461: 377-394 (1999).
91. Cui, Y., Konig, J., Buchholz, J. K., Spring, H., Leier, I. and Keppler, D.: Drug resistance and ATP-dependent conjugate transport mediated by the apical multidrug resistance protein, MRP2, permanently expressed in human and canine cells. Mol. Pharmacol., 55: 929-937 (1999).
92. Kool, M., de Haas, M., Scheffer, G. L., Scheper, R. J., van Eijk, M. J., Juijn, J. A., Baas, F. and Borst, P.: Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res., 57: 3537-3547 (1997).
93. Taniguchi, K., Wada, M., Kohno, K., Nakamura, T., Kawabe, T., Kawakami, M., Kagotani, K., Okumura, K., Akiyama, S. and Kuwano, M.: A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Res., 56: 4124-4129 (1996).
94. Han, J. Y., Lim, H. S., Yoo, Y. K., Shin, E. S., Park, Y. H., Lee, S. Y., Lee, J. E., Lee, D. H., Kim, H. T. and Lee, J. S.: Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecanpharmacokinetics and clinical outcome in patients with advanced nonsmall cell lung cancer. Cancer, 110: 138-147 (2007).
95. Sun, N., Sun, X., Chen, B., Cheng, H., Feng, J., Cheng, L. and Lu, Z.: MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother. Pharmacol., 65: 437-446 (2010).
96. Han, B., Gao, G., Wu, W., Gao, Z., Zhao, X., Li, L., Qiao, R., Chen, H., Wei, Q., Wu, J. and Lu, D.: Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. Lung Cancer, 72: 238-243 (2011).
97. Sprowl, J. A., Gregorc, V., Lazzari, C., Mathijssen, R. H., Loos, W. J. and Sparreboom, A.: Associations Between ABCC2 Polymorphisms and Cisplatin Disposition and Efficacy. Clin. Pharmacol. Ther., 91:1022-1026 (2012).
98. Gamelin, L., Capitain, O., Morel, A., Dumont, A., Traore, S., Anne le, B., Gilles, S., Boisdron-Celle, M. and Gamelin, E.: Predictive factors of oxaliplatin neurotoxicity: the involvement of the oxalate outcomepathway. Clin. Cancer Res., 13: 6359-6368 (2007).
99. Tian, C., Ambrosone, C. B., Darcy, K. M., Krivak, T. C., Armstrong, D. K., Bookman, M. A., Davis, W., Zhao, H., Moysich, K., Gallion, H. and DeLoia, J. A.: Common variants in ABCB1, ABCC2 and ABCG2 genes and clinical outcomes among women with advanced stage ovarian cancer treated with platinum and taxane-based chemotherapy: a Gynecologic Oncology Group study. Gynecol. Oncol., 124: 575-581 (2012).
100. Yasui, K., Mihara, S., Zhao, C., Okamoto, H., Saito-Ohara, F., Tomida, A., Funato, T., Yokomizo, A., Naito, S., Imoto, I., Tsuruo, T. and Inazawa, J.: Alteration in copy numbers of genes as a mechanism for acquired drug resistance. Cancer Res., 64: 1403-1410 (2004).
101. Wakamatsu, T., Nakahashi, Y., Hachimine, D., Seki, T. and Okazaki, K.: The combination of glycyrrhizin and lamivudine can reverse the cisplatin resistance in hepatocellular carcinoma cells through inhibition of multidrug resistance-associated proteins. Int. J. Oncol., 31: 1465-1472 (2007).
102. Zhang, Y. H., Wu, Q., Xiao, X. Y., Li, D. W. and Wang, X. P.: Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell. Cancer Lett., 291: 76-82 (2010).
103. Beretta, G. L., Benedetti, V., Cossa, G., Assaraf, Y. G., Bram, E., Gatti, L., Corna, E., Carenini, N., Colangelo, D., Howell, S. B., Zunino, F. and Perego, P.: Increased levels and defective glycosylation of MRPs in ovarian carcinoma cells resistant to oxaliplatin. Biochem. Pharmacol., 79: 1108-1117 (2010).
104. Tian, Q., Zhang, J., Tan, T. M., Chan, E., Duan, W., Chan, S. Y., Boelsterli, U. A., Ho, P. C., Yang, H., Bian, J. S., Huang, M., Zhu, Y. Z., Xiong, W., Li, X. and Zhou, S.: Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm. Res., 22: 1837-1853 (2005).
105. Aleksunes, L. M., Augustine, L. M., Scheffer, G. L., Cherrington, N. J. and Manautou, J. E.: Renal xenobiotic transporters are differentially expressed in mice following cisplatin treatment. Toxicology, 250: 82-88 (2008).
106. Moyer, A. M., Sun, Z., Batzler, A. J., Li, L., Schaid, D. J., Yang, P. and Weinshilboum, R. M.: Glutathione pathway genetic polymorphisms and lung cancer survival after platinum-based chemotherapy. Cancer Epidemiol. Biomarkers Prev., 19: 811-821 (2010).
107. Oguri, T., Isobe, T., Suzuki, T., Nishio, K., Fujiwara, Y., Katoh, O. and Yamakido, M.: Increased expression of the MRP5 gene is associated with exposure to platinum drugs in lung cancer. Int. J. Cancer, 86: 95-100 (2000).
108. Boiarskikh, U. A., K I Evshin, I. S., Sharipov, R. N., Komel'kov, A. V., Musatkina, E. A., Chevkina, E. M., Sukoian, M. A., Kolpakov, F. A., Kashkin, K. N. and Filipenko, M. L.: Prediction of a non-small cell lung cancer sensitivity to cisplatin and paclitaxel based on the marker genes expression. Mol. Biol. (Mosk.), 45: 652-661 (2011).
109. de Cremoux, P., Jourdan-Da-Silva, N., Couturier, J., Tran-Perennou, C., Schleiermacher, G., Fehlbaum, P., Doz, F., Mosseri, V., Delattre, O., Klijanienko, J., Vielh, P. and Michon, J.: Role of chemotherapy resistance genes in outcome of neuroblastoma. Pediatr. Blood Cancer, 48: 311-317 (2007).
110. Gradilone, A., Pulcinelli, F. M., Lotti, L. V., Trifirò, E., Martino, S., Gandini, O., Gianni, W., Frati, L., Aglianò, A. M. and Gazzaniga, P.: Celecoxib upregulates multidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr. Cancer Drug Targets, 8: 414-420 (2008).
111. Sugiyama, T. and Sadzuka, Y.: Theanine and glutamate transporter inhibitors enhance the antitumor efficacy of chemotherapeutic agents. Biochim. Biophys. Acta, 1653: 47-59 (2003).
112. Sekine, T., Watanabe, N., Hosoyamada, M., Kanai, Y. and Endou, H.: Expression Cloning and Characterization of a Novel Multispecific Organic Anion Transporter. J. Biol. Chem., 272: 18526-18529 (1997).
113. Sweet, D. H., Wolff, N. A. and Pritchard, J. B.: Expression Cloning and Characterization of ROAT1. J. Biol. Chem., 272: 30088-30095 (1997).
114. Wolff, N. A., Werner, A., Burkhardt, S. and Burckhardt, G.: Expression cloning and characterization of a renal organic anion transporter from winter flounder. FEBS Lett., 417: 287-291 (1997).
115. Sekine, T., Cha, S. H., Tsuda, M., Apiwattanakul, N., Nakajima, N., Kanai, Y. and Endou, H.: Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett., 429: 179-182 (1998).
116. Hosoyamada, M., Sekine, T., Kanai, Y. and Endou, H.: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol., 276: F122-F128 (1999).
117. Simonson, G. D., Vincent, A. C., Roberg, K. J., Huang, Y. and Iwanij, V.: Molecular cloning and characterization of a novel liver-specific transport protein. J. Cell Sci., 107: 1065-1072 (1994).
118. Ulu, R., Dogukan, A., Tuzcu, M., Gencoglu, H., Ulas, M., Ilhan, N., Muqbil, I., Mohammad, R. M., Kucuk, O. and Sahin, K.: Regulation of renal organic anion and cation transporters by thymoquinone in cisplatin induced kidney injury. Food Chem. Toxicol., 50: 1675-1679 (2012).
119. Klein, J., Bentur, Y., Cheung, D., Moselhy, G. and Koren, G.: Renal handling of cisplatin: interactions with organic anions and cations in the dog. Clin. Invest. Med., 14: 388-394 (1991).
120. Jacobs, C., Coleman, C. N., Rich, L., Hirst, K. and Weiner, M. W.: Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid. Cancer Res., 44: 3632-3635 (1984).
121. Ross, D. A. and Gale, G. R.: Reduction of the renal toxicity of cisdichlorodiammineplatinum(II) by probenecid. Cancer Treat. Rep., 63: 781-787 (1979).
122. Jacobs, C., Kaubisch, S., Halsey, J., Lum, B. L., Gosland, M., Coleman C. N. and Sikic, B. I.: The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. Cancer, 67: 1518-1524 (1991).
123. Ban, M., Hettich, D. and Huguet, N.: Nephrotoxicity mechanism of cisplatinum (II) diamine dichloride in mice. Toxicol. Lett., 71: 161-168 (1994).